QUEST DIAGNOSTICS $DGX Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $3.10B (Est. $3.05B) 🟢; +10.0% YoY 🔹 Adj. EPS: $3.00 (Est. $2.86) 🟢; +15.4% YoY 🔹 GAAP EPS: $2.78; +28.7% YoY Raises FY26 Guide: 🔹 Revenue: $12.07B-$12.11B (Est. $12B) 🟢 🔹 Adj. EPS: $11.25-$11.35 (Est. $11.19) 🟢 🔹 GAAP EPS: $10.21-$10.31 🔹 Operating Cash Flow: ~$1.90B 🔹 Capex: ~$550M Cash Flow: 🔹 Operating Cash Flow: $611M; +8.8% YoY 🔹 Capex: $166M; +15.0% YoY Other Q3 Metrics: 🔹 Adj. Oper Income: $517M (Est. $487M) 🟢 🔹 Adj. Oper Margin: 16.7% 🔹 Requisition Volume: +14.5% YoY 🔹 Organic Requisition Volume: +14.4% YoY 🔹 Revenue per Requisition: -4.2% YoY Announcements: 🔹 Quest laboratory test panels with over 50 biomarkers will be available through Apple Health later this year 🔹 Definitive agreement to acquire select outreach lab assets from a leading health system in the Northeastern U.S. 🔹 Launched a new AD-Detect test panel with pTau217, amyloid beta and APOE 🔹 Advanced Project Nova to the solutions-build phase; first lab deployment expected in fall 2027 Comments: 🔸 “With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”